Skip to content
AnalystLens

Exelixis Annual Report, Year Ended Dec 31, 2001

Filing Date
Filed March 20, 2002
Period End
December 31, 2001
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed March 20, 2002. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. (filed under the name Exelixis, Inc.) reported a 2001 net loss of $71.2 milliona on total revenues of $41.0 million, up from $24.8 million in 2000.

Research and development expenses rose to $82.7 millionb from $51.7 million, and the company reported an accumulated deficit of $201.2 million at December 31, 2001. Management states the company expects to incur net losses and negative operating cash flow for the foreseeable future, and that its current cash, cash equivalents, short-term investments and collaborator funding will maintain planned operations for at least the next two years. Cash, cash equivalents and short-term investments totaled $227.7 million at year-end.

The year's largest strategic event was the acquisition of Genomica Corporation, a bioinformatics company, in a stock-for-stock transaction valued at $110.0 millionc, completed January 8, 2002. Exelixis also acquired Artemis Pharmaceuticals GmbH in May 2001 for approximately $24.2 million, and recorded a $6.7 million in-process R&D charge in connection with it. Revenue depends heavily on collaborations: the filing states Bayer accounted for approximately 32% of 2001 revenues and Pharmacia approximately 31%.

The Pharmacia collaboration terminated in February 2002, eliminating roughly $9.0 milliond in annual research revenue that would otherwise have been payable for two more years. The company's most advanced proprietary program is DEAE Rebeccamycin, an in-licensed cancer compound from Bristol-Myers Squibb that is in Phase II trials conducted by the National Cancer Institute. The filing also notes that Exelixis has no manufacturing capability or prior clinical experience and will need to rely on third parties, and that a shareholder suit related to the Genomica merger is pending in Colorado state court.

Key Highlights

  1. 2001 net loss of $71.2 million; accumulated deficit of $201.2 million at December 31, 2001
  2. Total revenues rose to $41.0 million in 2001 from $24.8 million in 2000, driven by new Protein Design Labs and Bristol-Myers Squibb collaborations
  3. Research and development expenses increased to $82.7 million from $51.7 million; the company expects R&D spending to keep rising
  4. Cash, cash equivalents and short-term investments of $227.7 million at December 31, 2001, which management says will fund planned operations for at least two years
  5. Acquired Genomica Corporation in a $110.0 million stock transaction (completed January 8, 2002) and Artemis Pharmaceuticals GmbH for approximately $24.2 million
  6. Revenue concentration: Bayer approximately 32% and Pharmacia approximately 31% of 2001 revenues; Pharmacia collaboration terminated February 2002
  7. Lead clinical asset DEAE Rebeccamycin (in-licensed from Bristol-Myers Squibb) is in Phase II trials; company has no manufacturing or prior clinical trial experience

Frequently Asked Questions

  1. Is Exelixis profitable, and when does it expect to be?

    No. The company reported a net loss of $71.2 million for 2001 and an accumulated deficit of $201.2 million. It states it expects continued losses and negative operating cash flow for the foreseeable future, and that operating expenses will increase significantly in the near term.

  2. How much cash does Exelixis have, and is it enough?

    Cash, cash equivalents and short-term investments totaled $227.7 million at December 31, 2001. Management believes this, together with funding from collaborators, will sustain planned operations for at least the next two years, but notes that changes in the operating plan could require using capital sooner and that additional financing may be sought.

  3. What happened with the Pharmacia collaboration?

    The Pharmacia research collaboration was terminated by mutual agreement effective February 2002. Exelixis reacquired rights to the metabolism and Alzheimer's programs, and Pharmacia retained rights to selected earlier targets. The filing says this eliminates about $9.0 million in annual research revenue that would otherwise have been payable for two more years.

  4. What were the major acquisitions and their costs?

    Exelixis acquired Artemis Pharmaceuticals GmbH in May 2001 for approximately $24.2 million in stock, and Genomica Corporation in a stock-for-stock transaction valued at $110.0 million, completed January 8, 2002. The Genomica deal included a $2.7 million goodwill impairment charge and brought in $109.6 million of cash and investments.

  5. What are the main risks to the business?

    The filing highlights dependence on a small number of collaborators for nearly all revenue, the risk that milestones or royalties are not achieved, lack of experience in clinical development and manufacturing, lengthy FDA approval processes, intense competition, reliance on key personnel, and possible dilution from future equity or convertible financing. A Colorado state court lawsuit tied to the Genomica merger is also pending.